Agios Pharma (AGIO) Tops Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Agios Pharma (AGIO) PT Raised to $89 at Needham & Company
August 2, 2018 11:51 AM EDTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $89.00 (from $86.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Both TIBSOVO and IDHIFA are now approved in relapsed/refractory AML. Agios is focused on moving both drugs into earlier... More
